Difference between revisions of "Anal cancer"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "?Regimen |limit=10000|format=sum}} regimens" to "?Regimen |limit=10000|format=sum}} regimens") |
|||
| Line 26: | Line 26: | ||
=Definitive chemoradiotherapy for locally advanced disease= | =Definitive chemoradiotherapy for locally advanced disease= | ||
| + | ==Capecitabine, Mitomycin, RT {{#subobject:6c5a17 |Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | ===Regimen {{#subobject:9134b2|Variant=1}}=== | ||
| + | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 50%"|Study | ||
| + | !style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | |- | ||
| + | |[https://www.redjournal.org/article/S0360-3016(07)04703-7/fulltext Glynne-Jones et al. 2008] | ||
| + | | style="background-color:#91cf61" |Phase II | ||
| + | |- | ||
| + | |} | ||
| + | ====Chemoradiotherapy==== | ||
| + | *[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> PO BID on radiation days | ||
| + | *[[Mitomycin (Mutamycin)]] 12 mg/m<sup>2</sup> IV once on day 1 | ||
| + | *Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.8 Gy per day x 28 fractions (total dose: 50.4 Gy) | ||
| + | |||
| + | '''6-week course''' | ||
| + | ===References=== | ||
| + | # '''EXTRA:''' Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D; National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. Epub 2008 May 9. [https://www.redjournal.org/article/S0360-3016(07)04703-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18472366 PubMed] | ||
| + | |||
==Cisplatin, Fluorouracil, RT {{#subobject:6c5a17 |Regimen=1}}== | ==Cisplatin, Fluorouracil, RT {{#subobject:6c5a17 |Regimen=1}}== | ||
{{#subobject:6d1962 |Variant=1}} | {{#subobject:6d1962 |Variant=1}} | ||
Revision as of 02:49, 6 January 2019
| Section editors | |||
|---|---|---|---|
 |
Neeta K. Venepalli, MD, MBA Chicago, IL |
 |
Naina Singh, MD Chicago, IL |
9 regimens on this page
13 variants on this page
|
Guidelines
ESMO
- Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
Definitive chemoradiotherapy for locally advanced disease
Capecitabine, Mitomycin, RT
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Glynne-Jones et al. 2008 | Phase II |
Chemoradiotherapy
- Capecitabine (Xeloda) 825 mg/m2 PO BID on radiation days
- Mitomycin (Mutamycin) 12 mg/m2 IV once on day 1
- Concurrent radiation therapy: 1.8 Gy per day x 28 fractions (total dose: 50.4 Gy)
6-week course
References
- EXTRA: Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D; National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. Epub 2008 May 9. link to original article contains protocol PubMed
Cisplatin, Fluorouracil, RT
Fluorouracil, cisplatin, radiation therapy for anal cancer
Fluorouracil, Mitomycin, RT
Fluorouracil, mitomycin, radiation therapy for anal cancer
Radiation therapy
Radiation therapy for anal cancer